Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 17/20 | 0.73 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.71 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6439108 | 1.00 | PTGER4 (0.73) | PTGER4PTGER2PTGER3 | |
| SCHEMBL6802776 | 0.89 | PTGER4 (0.77) | PTGER4PTGER2PTGER3 | |
| SCHEMBL6802766 | 0.89 | PTGER4 (0.77) | PTGER4PTGER2PTGER3 | |
| SCHEMBL3680583 | 0.87 | PTGER4 (0.77) | PTGER4PTGER2PTGER3 | |
| SCHEMBL3680578 | 0.87 | PTGER4 (0.77) | PTGER4PTGER2PTGER3 | |
| SCHEMBL3673442 | 0.84 | PTGER4 (0.79) | PTGER4PTGER2PTGER3 | |
| SCHEMBL3673445 | 0.84 | PTGER4 (0.79) | PTGER4PTGER2PTGER3 | |
| SCHEMBL3675265 | 0.83 | PTGER4 (0.74) | PTGER4PTGER2PTGER3 | |
| SCHEMBL3675264 | 0.83 | PTGER4 (0.74) | PTGER4PTGER2PTGER3 | |
| SCHEMBL6166472 | 0.83 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453503-A4 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK & CO INC (US) | 2005-03-30 | — | — | EP | claimed |
| US-20040204590-A1 | Ep4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA LTD. (CA) | 2004-10-14 | — | — | US | claimed |
| EP-1453503-A2 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | Merck & Co., Inc. (US) | 2004-09-08 | — | — | EP | claimed |
| WO-2003047417-A2 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | claimed |
| US-20040204590-A1 | Ep4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA LTD. (CA) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204590-A1 | Ep4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGER3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.